Form IRANNOTICE DANAHER CORP /DE/
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
KeyBanc Remains Positive on Life Sciences as 'Strong' Earning Season Begins with Danaher (DHR) Report
July 21, 2022 11:40 AM EDTKeyBanc analyst Paul Knight comments "Bioprocess market leaders Sartorius (SRT3) and Danaher (DHR) published 2Q22 results this morning with strong revenue and EPS beats, providing a positive backdrop for the industry at large. Results clearly indicate bioprocess companies are witnessing high-levels of demand, making up for the headwinds posed... More
Cowen Reiterates Outperform Rating on Danaher (DHR), 'We expect the stock to react favorably'
July 21, 2022 10:22 AM EDTCowen analyst Dan Brennan reiterated an Outperform rating and $343.00 price target on Danaher (NYSE: DHR).
The analyst comments "Total organic growth of 9.5% well ahead of 'LSD%' guide and our 1.8%, with organic growth ex COVID testing ('base growth') of 8.0% ahead of our 4.3%.... More
Stifel Reiterates Hold Rating on Danaher (DHR), 'we are impressed with the company's ability to perform'
July 21, 2022 10:21 AM EDTStifel analyst Daniel Arias reiterated a Hold rating and {REMOVEPT} price target on Danaher (NYSE: DHR).
The analyst comments "Danaher reported 2Q22 revenues of $7.75B (+7.5% y/y), which was above Stifel ($7.12B) and consensus ($7.31B). Core revenue growth of 9.5% was ahead of expectations on... More
